Sökning: onr:"swepub:oai:DiVA.org:uu-380476" >
Diabetes in patient...
-
Brue, ThierryAix Marseille Univ, Inst Natl Sante & Rech Med INSERM, U1251, MMG, F-13005 Marseille, France;Hop Conception, AP HM, Ctr Reference Malad Rares Hypophyse HYPO, Dept Endocrinol, F-13005 Marseille, France
(författare)
Diabetes in patients with acromegaly treated with pegvisomant : observations from acrostudy
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
2018-11-24
-
SPRINGER,2019
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-380476
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-380476URI
-
https://doi.org/10.1007/s12020-018-1792-0DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PurposeTo explore the effects of pegvisomant (PEGV) on glucose metabolism in patients with acromegaly within ACROSTUDY, an international, observational, prospective safety surveillance study.MethodsPatients were retrospectively divided into two cohorts, with (DM group) or without diabetes mellitus (no-DM). Parameters of glucose metabolism and IGF-I values were analyzed yearly both cross-sectionally for 4 years (yrs) and longitudinally at 1 and 4-5yrs of PEGV treatment.ResultsAmong 1762 patients, 510 (28.9%) had DM before PEGV start. At cross-sectional analyses, in the DM group mean blood glucose was 140.058.7mg/dl at baseline, 116.4 +/- 44.8mg/dl at year 1 and 120.0 +/- 44.3mg/dl at yr 4. Mean HbA1c was 6.6 +/- 1.2 % at yr 1 vs. 7.0 +/- 1.4 % at baseline. HbA1c was above 6.5% in 61.9% at baseline and ranged from 45.4 to 53.8% at subsequent yearly time points. At the 4-yr longitudinal analysis, in the DM group (n=109), mean blood glucose decreased by 20.2mg/dl at yr 4, mean HbA1c was 7.0 +/- 1.5% at baseline vs. 6.8 +/- 1.4%. Patients achieved IGF-I normalization in 52.1% and 57.4% of cases in the DM and no-DM groups, respectively at 1 year. The mean daily PEGV dose (mg/day) was higher in the DM group (18.2 vs. 15.3) while the absolute change of IGF-I values from baseline was similar in both groups. PEGV was well tolerated in both groups without any unexpected AEs.Conclusions p id=Par4 Patients with DM had a moderate decrease in mean fasting glucose values during PEGV treatment.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Lindberg, AndersPfizer Hlth AB, Sollentuna, Sweden
(författare)
-
van der Lely, Aart JanErasmus Univ MC, Dept Med, Rotterdam, Netherlands
(författare)
-
Akerblad, Ann CharlottePfizer Hlth AB, Sollentuna, Sweden
(författare)
-
Koltowska-Häggström, Maria,1957-Uppsala universitet,Institutionen för kvinnors och barns hälsa(Swepub:uu)makot956
(författare)
-
Gomez, RoyPfizer, European Med Affairs, B-1050 Brussels, Belgium
(författare)
-
Droste, Michael
(författare)
-
Hey-Hadavi, JudithPfizer Inc, Endocrine Care, New York, NY USA
(författare)
-
Strasburger, Christian J.Campus Charite Mitte, Dept Med, Div Clin Endocrinol, Berlin, Germany
(författare)
-
Camacho-Hubner, CeciliaPfizer Inc, Endocrine Care, New York, NY USA
(författare)
-
Aix Marseille Univ, Inst Natl Sante & Rech Med INSERM, U1251, MMG, F-13005 Marseille, France;Hop Conception, AP HM, Ctr Reference Malad Rares Hypophyse HYPO, Dept Endocrinol, F-13005 Marseille, FrancePfizer Hlth AB, Sollentuna, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Endocrine: SPRINGER63:3, s. 563-5721355-008X1559-0100
Internetlänk
Hitta via bibliotek
Till lärosätets databas